Initial lurasidone dosing in acute schizophrenia: Pragmatic and trajectory-aware clinical implications. [PDF]
World J PsychiatryLiu Y, Liu T.
europepmc +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
Combinatorial classification model for predicting antipsychotic-induced hyperprolactinemia risk. [PDF]
Am J Transl ResWang Z +5 more
europepmc +1 more source
The use of different types of networks, alone and in combination, for drug target identification
British Journal of Pharmacology, EarlyView.Current therapeutic approaches often focus on targeting clinical symptoms or peripheral phenotypes rather than the underlying molecular mechanisms, or endophenotypes, that drive diseases. While symptom‐based drugs can alleviate discomfort, they do not necessarily alter disease progression and may overlook opportunities for prevention or early ...
Paolo Parini
wiley +1 more source
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms. [PDF]
Schizophr BullBugarski-Kirola D +3 more
europepmc +1 more source
Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
British Journal of Pharmacology, EarlyView.Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen +2 more
wiley +1 more source
Patient and Physician Perspectives on Pharmacotherapy in Parkinson's Disease Psychosis: A Mixed-Methods Exploratory Study. [PDF]
Pharmacy (Basel)Rose O +5 more
europepmc +1 more source
Fit to Be Tried: Bypassing Procedural Safeguards to Involuntarily Medicate Incompetent Defendants to Death [PDF]
, 2004 Jones, Cameron J.
core +1 more source